Human PD-L2 & TCR activator Recombinant Cell Line, CHO-K1 (CAT#: IOC-LX135)

Creative Biolabs has developed several immune checkpoint stable cell Lines expressing the most popular immune checkpoints to accelerate clients' immunotherapy discovery and clinical translation. Recombinant CHO-K1 cells constitutively expressing human PD-L2 (Programmed Cell Death 1 Ligand 2 or CD273, GenBank accession #NM_025239) and an engineered T-cell receptor (TCR) activator. Which can be used in binding assays and functional assay.

Stable cell lines for increased reliability and reproducibility;
Protein expression at the cell surface validated by FACS or WB;

Screen for activators or inhibitors of PD-1 signaling in a cellular context.

Human

CHO-K1

PD-L2 & TCR activator

The binding of Programmed Cell Death Protein 1 (PD-1), a receptor expressed on activated T-cells, to its ligands, PD-L1 and PD-L2, negatively regulates immune responses. PD-1 ligands are found on most cancers, and the PD-1:PD-L1/2 interaction inhibits T-cell activity and allows cancer cells to escape immune surveillance. The PD-1:PD-L1/2 pathway is also involved in regulating autoimmune responses, making these proteins promising therapeutic targets for a number of cancers, as well as multiple sclerosis, arthritis, lupus, and type I diabetes.